Hepatitis B vaccines: accomplishments, shortcomings, and future developments

References

• World Health Organization. The World Health Report Geneva, Switzerland: World Health Organization, 1997.
   Google Scholar
• World Health Organization. Hepatitis B. 1,1brld Health Organization Fact Sheet 204 (Revised October 2000). WHO website. 2000. who.int/inf-fs/en/fact204.html [Accessed February 2008]
   Google Scholar
• Lok AS. Chronic hepatitis B. NEng1JMed2002; 346: 1682–1683.
   Google Scholar
• Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnich AI. A serum antigen (Australian antigen) in Down's syndrome, leukemia and hepatitis. Ann IntMed1967; 66:924–931.
   Google Scholar
• Hilleman MR. Plasma-derived hepatitis B vaccine a breakthrough in preventive medecine. In: Ellis R, ed. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker, 1992: 17–39.
   Google Scholar
• Chan CY, Lee SD, Lo KJ. Legend of hepatitis B vaccination: the Taiwan experience. J Gastroenterol Hepa to/2004; 19: 121–126.
   Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Wral Hep2004;11: 97–107.
   Google Scholar
• Duclos P. Safety of immunization and adverse events following vaccination against hepatitis B. JHepato12003; 39:S83–S88.
   Google Scholar
• Adkins JC, WagstaffAJ. Recombinant hepatitis B vaccine. A review of its immunogenicity and protective efficacy against hepatitis B. Biodrugs 1998; 10:137–158.
   Google Scholar
• Cox RJ, Bokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004; 59: 1–15.
   Google Scholar
• Williams JL, Braden DA, Cagle HH, et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Uccine2003; 21:3208–3211.
   Google Scholar
• Noad R, Roy P. Virus-like particles as immunogens. Trends Immunol 2003; 11:438–444.
   Google Scholar
• Vanlandschoot P, Cao T, Leroux-Roels G. The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure. Antiviral Res 2003; 60:67–74.
   Google Scholar
• Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. SeminCancerBio/1996; 7:373–382.
   Google Scholar
• Gavilanes F, Gonzales-Ros JM, Peterson DL. Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins. JBiol Chem 1982; 257:7770–7777.
   Google Scholar
• Skelly J, Howard CR, Zuckerman AJ. Hepatitis B polypeptide vaccine preparation in micelle form. Nature1981; 290:51–54.
   Google Scholar
• Manesis EK, Cameron CH, Gregoriadis G. Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen. FEBSLetters 1979; 102: 107–111.
   Google Scholar
• Baijot M. Protein arrangement in the yeast-derived hepatitis B surface antigen particles. PhD thesis. Université Catholique de Louvain, Belgium, 1991.
   Google Scholar
• Desombere I, Willems A, Gijbels Y, Leroux-Roels G. Partial delipidation improves the T-cell antigenicity of hepatitis B surface antigen. J Wro/2006; 80:3506–3514.
   Google Scholar
• 20. Jochum C, Voth R, Rossol S, et al. Immunosuppressive function of hepatitis B antigens in vitro: role of endoribonuclease V as one potential trans inactivator for cytokines in macrophages and human hepatoma cells. J Wro/1990; 64: 1956–1963.
   Google Scholar
• Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Leroux-Roels G. Yeast derived hepatitis B surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor. J Gen Wro/2002; 83: 1281–1289.
   Google Scholar
• Vanlandschoot P, Van Houtte F, Roobrouck A, et al. LPS binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipid moiety of the particles. J Gen Wro/2002; 83:2279–2289.
   Google Scholar
• Vanlandschoot P, Roobrouck A, Van Houtte F, Leroux-Roels G. Recombinant HBsAg, an apoptotic-like lipoprotein, interferes with the LPS-induced phosphorylation of ERK-1/2 and JNK-1/2 in monocytes. BiochemBiophys Res Comm2002; 297:486–491.
   Google Scholar
• Diminsky D, Schrimbeck R, Reimann J, Bärenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansuela polymorpha): composition, structure and immunogenicity. Uccine 1997; 15: 637–647.
   Google Scholar
• Copland MJ, Baird MA, Rades T, et al Liposomal delivery of antigen to human dendritic cells. Uccine2003; 21:883–890.
   Google Scholar
• Foged C, Arigita C, Sundblad A, Jiskoor W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. 1.,h ccine2004; 16: 1903–1913.
   Google Scholar
• Chen X, Doffek K, Sugg SL, Shilyansky J. Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol 2004; 173:2985–2994.
   Google Scholar
• De Meyer S, Gong ZJ, Suwandhi W, Van Pelt J, Soumillion A, Yap SH. Organ and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytes. J Wral Hepat1997; 4: 145–153.
   Google Scholar
• 29. Martinetti M, Cuccia M, Daielli C, et al. Anti-HBV neonatal immunization with recombinant vaccine. Part II. Molecular basis of the impaired alloreactivity. Tccine 1995; 13:555–560.
   Google Scholar
• De Silvestri A, Pasi A, Martinetti M, et al. Family study of non-responsiveness to hepatitis B vaccine confirms the importance of HLA class III C4A locus. Genes and Immunity2001; 2:367–372.
   Google Scholar
• Hohler T, Stradmann-Bellinghausen B, Starke R, etal C4A deficiency and nonresponse to hepatitis B vaccination. J Hepatol 2002; 37: 387–392.
   Google Scholar
• Vanlandschoot P, Van Houtte F, Roobrouck A, Steller F, Gavilanes F, Leroux-Roels G. A temperature-dependent inhibitory activity of serum on the capacity of Saccharomyces cerevisiae-derived hepatitis B surface antigen to bind to monocytes. Arch Wro/2005; 150:247–259.
   Google Scholar
• Milich DR, Leroux-Roels G. Immunogenetics of the response to HBsAg vaccination. AutoimmunityReview92003; 2:248–257.
   Google Scholar
• Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. JImmuno11995; 154:520–529.
   Google Scholar
• 35.Salazar M, Deulofeut H, Granja C, et al Normal HBsAg presentation and T-cell defect in the immune response of nonresponders. 36 lmmunogenetics 1995; 41:366–374.
   Google Scholar
• Desombere I, Gijbels Y, Verwulgen A, Leroux-Roels G. Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines. Clin Ey, Immuno12000; 122:390–399.
   Google Scholar
• Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology2000; 32:1189–1195.
   Google Scholar
• Chemin I, Vermot-Desroches C, Baginski I, eta]. Monitoring of early events of experimental woodchuck hepatitis infection: studies of peripheral blood mononuclear cells by cytofluorometry and PCR. FEMSImmunol Med Mcrobio11993; 7:241–249.
   Google Scholar
• Lew YY, Michalak TI. In vitro and in vivo infectivity and pathogenicity of the lymphoid cell-derived woodchuck hepatitis virus. J Wro/ 2001; 75: 1770–1782.
   Google Scholar
• ParanN, Geiger B, Shaul Y. HBV infection of cell culture: evidence for multivalent and cooperative attachment. EMI30 J2001; 20: 4443–4453.
   Google Scholar
• Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B surface antigen. JBiomedSci2001; 8:237–247.
   Google Scholar
• Zuckerman JN, Zuckerman AJ. Mutations of the surface protein of hepatitis B virus. Antiviral Res2003; 60:75–78.
   Google Scholar
• Dandri M, Burda MR, Torok E, eta]. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology2001; 33:981–988.
   Google Scholar
• Mercer DF, Schiller DE, Elliott JF, eta]. Hepatitis C virus replication in mice with chimeric human livers. NatMed2001; 7:927–933.
   Google Scholar
• Tateno C, Yoshizane Y, Saito N, eta]. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165:901–912.
   Google Scholar
• Meuleman P, Libbrecht L, De Vos R, et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology2005; 41: 847–856.
   Google Scholar
• Milich DR, McNamara MK, McLachlan A, Thornton GB, Chisari FV. Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. ProcNatl Acad Sci USA1985; 82:8168–8172.
   Google Scholar
• Milich DR, McLachlanA, Chisari FV, Kent SB, Thorton GB. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol 1986; 137:315–322.
   Google Scholar
• Leroux-Roels G, Desombere I, De Tollenaere G, et al. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults. Uccine 1997; 15:1724–1731.
   Google Scholar
• Leroux-Roels G, Desombere I, Cobbaut L, eta]. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines. Uccine 1997; 15: 1732–1736.
   Google Scholar
• Shouval D. Hepatitis B vaccines. JHepato12003; 39:S70–S76.
   Google Scholar
• Heineman TC, Clements-Mann ML, Poland GA, eta]. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Uccine 1999; 17:2769–2778.
   Google Scholar
• Lewis DJ, Eiden JE, Goilav C, Langenberg AG, Suggett F, Griffin GE. Rapid and frequent induction of protective immunity exceeding UK recommendations for healthcare settings by MF59-adjuvanted hepatitis B vaccine. Commun Dis Public Health 2003; 6:320–324.
   Google Scholar
• Thoelen S, Van Damme P, Mathei C, eta]. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Uccine 1998; 16: 708–714.
   Google Scholar
• Ambrosch F, Wiedermann G, Kundi M, eta]. A hepatitis B vaccine formulated with a novel adjuvant system. Uccine2000; 18:2095–2101.
   Google Scholar
• Boland G, Beran J, Lievens M, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with A504. Uccine 2004; 23:316–320.
   Google Scholar
• Hilleman MR. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Uccine2003; 21: 4626–4649.
   Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, eta]. Efficacy of the RTS,S/ASO2A vaccine against Plasmodium Liciparuminfection and disease in young African children: randomised controlled trial. Lancet2004; 364: 1411–1420.
   Google Scholar